慢性粒单核细胞白血病或BCR-ABL阴性骨髓增殖性肿瘤患者的肾脏受累
中位随访24个月后,61%患者恶性肿瘤稳定,但22%进展至终末期肾衰竭。
要点
- CMML/MPN患者可发生多种肾脏病变,包括AKI、CKD和尿检异常。
- 肾活检常见寡免疫复合物肾小球硬化、髓外造血及小管间质纤维化。
- 部分患者可进展至终末期肾衰竭,需密切监测肾功能。
核心结论
- CMML/MPN相关肾脏并发症表现异质,肾活检可能有助于识别预防肾纤维化的新分子靶点。
主要发现
- 肾活检(n=14)显示寡免疫复合物肾小球硬化(n=5)、髓外造血(n=6)、小管萎缩和间质纤维化伴多形性炎症(n=8)。
- CD61免疫染色证实5/8例患者肾小球或间质内有巨核细胞浸润。
- 其他肾小球病变包括IgA肾病(n=2)和AA淀粉样变性(n=1),1例有CMML大量肾脏浸润。
临床怎么用
- 对CMML/MPN患者应监测肾功能和尿检,出现肾脏异常时考虑肾活检以明确病理类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The identification of specific molecular signatures and the development of new targeted drugs have changed the paradigm of onco-nephrology, now allowing a multiscale approach of kidney involvement related to hematologic malignancies relying on combined hematologic and molecular assessments. In this study, we aimed to refine the spectrum of kidney disorders associated with chronic myelomonocytic leukemia (CMML) or BCR-ABL-negative myeloproliferative neoplasms (MPNs), 2 very rare conditions scarcely described. METHODS: Case series. Patients with myeloid neoplasms who were referred to Toulouse University Hospital Nephrology Unit and were diagnosed with acute kidney injury (AKI), chronic kidney disease (CKD), or urine abnormalities were retrospectively included. RESULTS: Eighteen patients (males n=13, CMML n=8, essential thrombocytosis [ET] n=7, polycythemia vera [PV] n=1, and myelofibrosis n=2) developed kidney disease 7.7±2 years after the diagnosis of the malignancy. Twelve patients had AKI at presentation. Eight patients had glomerular presentation (high-range proteinuria 33%, microscopic hematuria 56%). Kidney biopsy (n=14) showed various patterns, including pauci-immune glomerulosclerosis (n=5), extramedullary hematopoiesis (n=6), or tubular atrophy and interstitial fibrosis with polymorphic inflammation (n=8). Immunostaining of CD61 confirmed the infiltration of megakaryocytes within glomeruli or interstitium in 5 of 8 patients. Other pictures of glomerulopathy were identified in 3 patients (IgA nephropathy n=2, AA amyloidosis n=1). Massive kidney infiltration by CMML was identified in 1 patient. After a mean follow-up of 24±6 months, malignancy was considered as stable in 11 patients (61%), but 22% of patients had progressed to end-stage renal failure. The remaining had persistently reduced kidney function. No correlation between the malignancy and the renal presentation and outcomes could be identified. CONCLUSIONS: Kidney complications of CMML/MPN are heterogenous, and kidney biopsy may help to identify new molecular targets to prevent the development of kidney fibrosis.
引用
- Belliere J, Colombat M, Kounde C, et al. Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative Neoplasms. Kidney Int Rep. 2020. PMID: 33732988. doi:10.1016/j.ekir.2020.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。